Duplicate Document
This document appears to be a copy. The original version is:
EFTA Document EFTA01355299Case File
efta-efta01355299DOJ Data Set 10CorrespondenceEFTA Document EFTA01355299
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01355299
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Summary
Ask AI About This Document
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
GLDUS127 Annandale Capital
SOF IV — Project Klein
Exclusive deal
Expected Glosing Date:
June 2018
El Fund Secondary
11(GP-led Secondary
K
Single Asset Deal
Seller type:
Alternative funds
Key investment data
Transaction summary
Invested Capital at dose
E60-100m (US$80-120m)
Number of companies
4
Discount to NAV at close
>5%
Strategy
Mid-market buyout
Gross multiple at close
1.1x
Region
Europe / UK
0/0 funded at close
80%
Industries
Business services / Healthcare services
Use of leverage
No
Average age at purchase
9 years
Description
- Motivated quality GP aiming to recapitalize and extend their 2007 mid-
market pan-European fund while providing liquidity to LPs
- Key value driver is largest independent UK premium distributor in its
segment, well positioned to benefit from market tailwinds
- Second largest asset is a network of medical and cosmetics UK clinics
with a private and affluent customer base
- The portfolio also includes an Italian digital marketing company and a
management consulting company with blue chip customers
- Glendower Capital retains discretion on use of follow-on capital
Investment rationale / Glendower Team angle
Glendower Team angle
- Ability to quickly deliver a bespoke solution leveraging Glendower's
track record in complex transactions
- Ability to perform extensive diligence, including onsite visits, full access
to companies' management and industry specialists
- Long 15-year relationship with the GP founder
Investment rationale
- Four well-invested companies positioned to capture growth
opportunities arising from ongoing changes in industry landscape
- Key value driver led by industry veteran with a solid track record
- Value-add potential from recently implemented cost efficiency initiatives
- Opportunity to invest in identified follow-ons at closing, and to contribute
additional capita! to exploit market dislocations
Fot disci.m.sSon istaposes«..4y. The inwiatmant ~tamd agave I .W s. flot close-i. and the is no øuwantee tbal
investinent w3E cwipleaeo,- forre pala og a kamre 'rivest-ed poitfo4m cx Mel g Al bu avaliatge 4,. after furt1wi
due diligence.. prove surtable for :30F nr This slide hauld be reed and teine-wc-d in conjundion with the Important Information and "Important Performance Intornabon and • Notes to Investment Performance sections.
Glendower
Capital
STRICTLY CONFIDENTIAL
C0NFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
DB-SDNY-0040352
CONFIDENTIAL
SDNY_GM_00186536
EFTA01355299
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.